Shots:  The submission was based on the results from the P-III clinical trials evaluating the equivalence & similarity of CT-P47 vs Actemra (tocilizumab) in patients (n=471) with rheumatoid arthritis (RA)  Moreover, based on these results the company also expects to accelerate its marketing authorization application across Canada & other countries. The company expects to receive…